Table 2.
Pathologic response following neoadjuvant therapy
| Neoadjuvant chemotherapy | Neoadjuvant SBRT (dose / fractions) | Pathologic response (Evans’ criteria) | |
|---|---|---|---|
|
01 |
Gem./Cape. |
36 Gy / 3 |
IV |
|
02 |
Gem./Cape. |
36 Gy / 3 |
IV |
|
03 |
FOLFIRINOX, Gem./Abraxane |
36 Gy / 3 |
IV |
|
04 |
Gem./Erlotinib |
24 Gy / 1 |
III |
|
05 |
Gem./Cape. |
24 Gy / 1 |
III |
|
06 |
Gem. |
24 Gy / 1 |
IIb |
|
07 |
FOLFIRINOX |
36 Gy / 3 |
IIb |
|
08 |
N/A |
36 Gy / 3 |
IIa |
|
09 |
Gem./Cape. |
36 Gy / 3 |
IIa |
|
10 |
Gem./Cape. |
24 Gy / 1 |
IIa |
|
11 |
Gem./Cape. |
24 Gy / 1 |
IIa |
| 12 | Gem./Cape. | 30 Gy /3 | IIa |
25% of patients achieved a complete pathologic (pCR) response to neoadjuvant therapy (Evans’ grade: IV), and an additional 16.7% of patients had >90% tumor cell destruction (Evans’ grade: III). In total, 58.3% of patients had at least 50% of tumor cell destruction (Evans’ Grade: IIb – IV). For those achieving pCR, SBRT dose was 36 Gy in 3 fractions and neoadjuvant chemotherapy was gemcitabine-based. [Abbreviations: Gem Gemcitabine, Cape Capecitabine].